These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 9831367)
1. Interferon and thymosin combination therapy in naive patients with chronic hepatitis C: preliminary results. Moscarella S; Buzzelli G; Romanelli RG; Monti M; Giannini C; Careccia G; Marrocchi EM; Zignego AL Liver; 1998 Oct; 18(5):366-9. PubMed ID: 9831367 [TBL] [Abstract][Full Text] [Related]
2. Thymosin-alpha 1 plus interferon-alpha for naive patients with chronic hepatitis C: results of a randomized controlled pilot trial. Andreone P; Gramenzi A; Cursaro C; Felline F; Loggi E; D'Errico A; Spinosa M; Lorenzini S; Biselli M; Bernardi M J Viral Hepat; 2004 Jan; 11(1):69-73. PubMed ID: 14738560 [TBL] [Abstract][Full Text] [Related]
3. Combination thymosin alpha 1 and lymphoblastoid interferon treatment in chronic hepatitis C. Rasi G; DiVirgilio D; Mutchnick MG; Colella F; Sinibaldi-Vallebona P; Pierimarchi P; Valli B; Garaci E Gut; 1996 Nov; 39(5):679-83. PubMed ID: 9026482 [TBL] [Abstract][Full Text] [Related]
4. Combination therapy with thymosin alpha1 and interferon for the treatment of chronic hepatitis C infection: a randomized, placebo-controlled double-blind trial. Sherman KE; Sjogren M; Creager RL; Damiano MA; Freeman S; Lewey S; Davis D; Root S; Weber FL; Ishak KG; Goodman ZD Hepatology; 1998 Apr; 27(4):1128-35. PubMed ID: 9537454 [TBL] [Abstract][Full Text] [Related]
5. Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: a multicenter, controlled, randomized trial. Le Groupe D'étude et De Traitement du Virus De L'hépatite C (Get.Vhc). Payen JL; Izopet J; Galindo-Migeot V; Lauwers-Cances V; Zarski JP; Seigneurin JM; Dussaix E; Voigt JJ; Selves J; Barange K; Puel J; Pascal JP Hepatology; 1998 Dec; 28(6):1680-6. PubMed ID: 9828235 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of a short-term ribavirin plus interferon alpha combination therapy followed by interferon alpha alone in previously untreated patients with chronic hepatitis C: a randomized multicenter trial. Berg T; Hoffmann RM; Teuber G; Leifeld L; Lafrenz M; Baumgarten R; Spengler U; Zeuzem S; Pape GR; Hopf U Liver; 2000 Dec; 20(6):427-36. PubMed ID: 11169056 [TBL] [Abstract][Full Text] [Related]
7. A multicenter, randomized, controlled trial of interferon alfacon-1 compared with alpha-2a-interferon in Chinese patients with chronic hepatitis C virus infection. Yao GB; Fu XX; Tian GS; Xu DZ; Hao LJ; Huangfu YS; Su CX J Gastroenterol Hepatol; 2000 Oct; 15(10):1165-70. PubMed ID: 11106097 [TBL] [Abstract][Full Text] [Related]
8. The combined treatment of interferon alpha-2a and thymosin alpha 1 for chronic hepatitis C: the 48 weeks end of treatment results. Kullavanuaya P; Treeprasertsuk S; Thong-Ngam D; Chaermthai K; Gonlachanvit S; Suwanagool P J Med Assoc Thai; 2001 Jun; 84 Suppl 1():S462-8. PubMed ID: 11529376 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment. Campistol JM; Esforzado N; Martínez J; Roselló L; Veciana L; Modol J; Casellas J; Pons M; de Las Cuevas X; Piera J; Oliva JA; Costa J; Barrera JM; Bruguera M Nephrol Dial Transplant; 1999 Nov; 14(11):2704-9. PubMed ID: 10534516 [TBL] [Abstract][Full Text] [Related]
10. Treatment with interferon-alpha2b of naive non-cirrhotic patients with chronic hepatitis C according to viraemia and genotype. Results of a randomized multicentre study. The North West Italian Hepatological Group. Saracco G; Ciancio A; Ghisetti V; Rocca G; Cariti G; Andreoni M; Tabone M; Roffi L; Calleri G; Ballaré M; Terreni N; Sartori M; Tappero GF; Traverso A; Poggio A; Orani A; Maggi G; Di Napoli A; Arrigoni A; Rizzetto M; Eur J Gastroenterol Hepatol; 2001 Feb; 13(2):149-55. PubMed ID: 11246614 [TBL] [Abstract][Full Text] [Related]
11. Interferon alpha-2b in combination with ribavirin for the treatment of chronic hepatitis C: assessment of virological, biochemical and histological treatment response. Petrenkiene V; Gudinaviciene I; Jonaitis L; Kupcinskas L Medicina (Kaunas); 2004; 40(6):538-46. PubMed ID: 15208476 [TBL] [Abstract][Full Text] [Related]
12. Comparison of the efficacy of thymosin alpha-1 and interferon alpha in the treatment of chronic hepatitis B: a meta-analysis. Yang YF; Zhao W; Zhong YD; Yang YJ; Shen L; Zhang N; Huang P Antiviral Res; 2008 Feb; 77(2):136-41. PubMed ID: 18078676 [TBL] [Abstract][Full Text] [Related]
13. The pattern of response to interferon alpha (alpha-IFN) predicts sustained response to a 6-month alpha-IFN and ribavirin retreatment for chronic hepatitis C. TVVH Study Group. Cavalletto L; Chemello L; Donada C; Casarin P; Belussi F; Bernardinello E; Marino F; Pontisso P; Gatta A; Alberti A J Hepatol; 2000 Jul; 33(1):128-34. PubMed ID: 10905596 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of triple therapy with thymalfasin, peginterferon alpha-2a, and ribavirin for the treatment of hispanic chronic HCV nonresponders. Poo JL; Sánchez Avila F; Kershenobich D; García Samper X; Torress-Ibarra R; Góngora J; Cano C; Parada M; Uribe M Ann Hepatol; 2008; 7(4):369-75. PubMed ID: 19034238 [TBL] [Abstract][Full Text] [Related]
15. Long-term outcomes of thymosin-alpha 1 and interferon alpha-2b combination therapy in patients with hepatitis B e antigen (HBeAg) negative chronic hepatitis B. Saruc M; Ozden N; Turkel N; Ayhan S; Hock LM; Tuzcuoglu I; Yuceyar H J Pharm Sci; 2003 Jul; 92(7):1386-95. PubMed ID: 12820143 [TBL] [Abstract][Full Text] [Related]
16. A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C not responding to interferon alone. Saracco G; Ciancio A; Olivero A; Smedile A; Roffi L; Croce G; Colletta C; Cariti G; Andreoni M; Biglino A; Calleri G; Maggi G; Tappero GF; Orsi PG; Terreni N; Macor A; Di Napoli A; Rinaldi E; Ciccone G; Rizzetto M Hepatology; 2001 Jul; 34(1):133-8. PubMed ID: 11431744 [TBL] [Abstract][Full Text] [Related]
17. Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study. Farrell GC; Bacon BR; Goldin RD Hepatology; 1998 Apr; 27(4):1121-7. PubMed ID: 9537453 [TBL] [Abstract][Full Text] [Related]
18. Retreatment with interferon-alpha and ribavirin in primary interferon-alpha non-responders with chronic hepatitis C. Teuber G; Berg T; Hoffmann RM; Leifeld L; Lafrenz M; Spengler U; Pape GR; Hopf U; Zeuzem S Digestion; 2000; 61(2):90-7. PubMed ID: 10705172 [TBL] [Abstract][Full Text] [Related]
19. Combination of ribavirin and interferon-alfa surpasses high doses of interferon-alfa alone in patients with genotype-1b-related chronic hepatitis C. Pol S; Nalpas B; Bourlière M; Couzigou P; Tran A; Abergel A; Zarski JP; Berthelot P; Bréchot C Hepatology; 2000 Jun; 31(6):1338-44. PubMed ID: 10827161 [TBL] [Abstract][Full Text] [Related]
20. Chronic hepatitis C virus infection in renal transplant: treatment and outcome. Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]